Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Mayo Clinic
Study ID
NCT07317154
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Recurrent Respiratory Papillomatosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Autologous HPV6 E6-and E7-derived peptide-loaded dendritic cell — BIOLOGICAL
    Each patient will receive 5 doses autologous immunotherapy intradermally.

Study Details

The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients

Key Dates

Start date
Apr 30, 2026
Status verified
Mar 2026
Primary completion
Nov 30, 2026
Completion
Feb 28, 2027

Study Design

Enrollment
9 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Disease Group
    Patients with clinically confirmed human papilloma virus (HPV)6+ Recurrent Respiratory Papillomatosis (RRP) in the laryngeal mucosa at the time of recruitment, and patients with records of RRP in laryngeal mucosa at least once in the past 6-12 months at the time of recruitment, will receive immunotherapy.

Primary Outcome Measure

Number of participants with treatment-related adverse events [ Time Frame: 20 months ]

Central Contacts

  • Debbie Ryan, CCRP
    480-342-1208

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in ArizonaScottsdaleArizona85259
Debbie Ryan, CCRP
480-342-1208
David G Lott, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Scottsdale, AZ

By research site
Mayo Clinic in Arizona· Scottsdale, AZ

Related Studies